We previously developed a bioinformatic framework for the identification of novel molecular vulnerabilities for disease stratification and treatment and observed SPINK2, a serine protease inhibitor Kazal-type 2, as a novel and promising candidate target in AML, with particularly pronounced effects in complex karyotype patients. This evidence concerns the gene SPINK2 and acute myeloid leukemia.